Actimed Therapeutics Secures Significant New Patent, Extending IP Coverage of its Lead Compound for Use in Key Indication

London, UK – 4 May 2022: Actimed Therapeutics Ltd, a clinical stage company focused on bringing innovation to the treatment of muscle wasting disorders, today announced the grant of a new UK Patent (GB 2593902 B) covering new salts of S-pindolol for use in the treatment or prevention of cachexia with an expiry date in 2040. An international patent application has also been filed under the Patent Cooperation Treaty (PCT) and was published in October 2021, which seeks to extend patent protection for new S-pindolol salts to all relevant major international markets out to 2041.
More info >>